CHMP recommends against Mirati's KRAS rival, in favor of Pfizer's RSV vaccine, other drugs
The European Medicines Agency’s human medicines committee (CHMP) recommended against conditional authorization for Mirati’s KRAS G12C inhibitor Krazati in non-small cell lung cancer this week, while giving the thumbs-up to 14 other drugs, including Pfizer’s RSV vaccine.
CHMP said on Friday that there were uncertainties about how well Krazati (adagrasib) worked, adding that “comprehensive data for this medicine were not yet available” and criteria for a conditional marketing authorization were unmet.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.